Frequency and Severity of Pleural Effusion Associated With the Use of Dasatinib in Patients With Chronic Myeloid Leukemia. A Descriptive, Mexican Multicenter Study (PASS)

Bristol-Myers Squibb (BMS)

Status: Completed

Conditions: Leukemia

Treatments: Drug: Dasatinib

Study type: Observational

Funder types: Industry

Identifiers

NCT02546791

CA180-556

Details and patient eligibility

About

This is a retrospective, multicenter, descriptive analysis of patients with a diagnosis of chronic myeloid leukemia, treated with dasatinib for at least 45 days. The study will include 100 patients treated in different public centers in the Mexican Republic.

Enrollment: 101 patients

Sex: All

Ages: 15+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Men and women ≥15 years of age
• Diagnosis of chronic myeloid leukemia in any phase that used dasatinib at any time between January 2008 and November 2014
• Have received dasatinib as part of their first-line or second-line treatment for at least 45 days

Exclusion criteria

• Patients who received dasatinib as part of any clinical trial
• Patients who do not have complete data on the data collection sheet
• Patients who do not have medical records available at the moment of the data verification

Trial design

101 participants in 1 patient group

Chronic myeloid leukemia patients treated with Dasatinib

Description:

patients with a diagnosis of chronic myeloid leukemia treated with Dasatinib for at least 45 days

Treatment:

Drug: Dasatinib